Stock prices in the biotech sector are getting carpet-bombed as
investors bail out of the sector, but this is still fundamentally a
data-driven industry where good data almost always win out in the end.
To that end, Neurocrine Biosciences' (NASDAQ:NBIX) recent run of good news should encourage shareholders even as the market has turned cold on these once-outperforming shares.
Neurocrine
Biosciences remains a challenging biotech to value, due in part to the
fact that the markets that the company's lead drugs are targeting could
prove to be substantially more robust than they seem at present. Even
with what I believe to be relatively conservative assumptions, though,
Neurocrine's shares look appealingly undervalued.
Click here for more:
Neurocrine Biosciences Racks Up Some Much-Needed Good News
No comments:
Post a Comment